STORE Capital Corp
Change company Symbol lookup
Select an option...
STOR STORE Capital Corp
SWCH Switch Inc
SWKS Skyworks Solutions Inc
MSB Mesabi Trust
ESS Essex Property Trust Inc
WRAP Wrap Technologies Inc
GOOG Alphabet Inc
MMMB MamaMancini's Holdings Inc
RXT Rackspace Technology Inc
RKT Rocket Companies Inc
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Mid Cap Blend
Company profile

STORE Capital Corporation is an internally managed net-lease real estate investment trust. The Company is engaged in the acquisition, investment and management of single tenant operational real estate (STORE) properties. As of December 31, 2016, the Company owned a portfolio that consisted of investments in 1,660 property locations operated by 360 customers across 48 states. Its customers operate across a range of industries within the service, retail and manufacturing sectors of the United States economy, with restaurants, early childhood education centers, movie theaters, health clubs and furniture stores. The Company's portfolio includes investments in approximately 1,330 property locations operated by over 300 customers across approximately 50 states. The Company provides real estate financing solutions principally to businesses that own STORE properties and operate within the broad-based service, retail and industrial sectors of the United States economy.

Postmarket

Last Trade
Delayed
$30.85
-0.01 (-0.03%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$30.86
Day's Change
-0.13 (-0.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
30.96
Day's Low
30.27
Volume
(Light)
Volume:
1,622,430

10-day average volume:
2,246,953
1,622,430

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

4:18 pm ET November 18, 2020 (BusinessWire) Print

Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN) investors concerning the Company's possible violations of the federal securities laws.

If you suffered a loss on your Supernus investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/supernus-pharmaceuticals-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On November 9, 2020, after the market closed, Supernus disclosed receipt of a complete response letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding its new drug application ("NDA") for SPN-812 for the treatment of ADHD in pediatric patients aged 6-17 years old. According to the CRL, the NDA "is not ready for approval in its present form." Among other things, "[t]he primary issue cited in the SPN-812 CRL relates to the Company's in-house laboratory that conducts analytical testing, which recently moved to a new location."

On this news, Supernus's stock price fell $3.88 per share, or approximately 16%, to close at $21.08 per share on November 10, 2020, thereby injuring investors.

Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice: Persons with non-public information regarding Supernus should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.

About GPM

Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM's attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201118006146/en/

SOURCE: Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com 
shareholders@glancylaw.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.